3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
8
Head & Neck
5
Gastrointestinal
4
Thoracic
3
Gynecologic
3
Sarcoma
2
Other hematologic neoplasm
2
Classical hematology
2
Plasma cell
1
Myeloid
1
Lymphoid
1
Conditions
Sarcoma
433
Osteosarcoma
132
Sarcoma, Ewing
88
Melanoma
80
Rhabdomyosarcoma
77
Neoplasms
72
Neuroblastoma
62
Gastrointestinal Stromal Tumors
61
Colorectal Neoplasms
60
Breast Neoplasms
60
Bone Neoplasms
60
Ovarian Neoplasms
58
Glioblastoma
56
Neoplasm Metastasis
52
Liposarcoma
51
Dendritic Cell Sarcoma, Interdigitating
45
Leiomyosarcoma
43
Gliosarcoma
43
Carcinoma, Non-Small-Cell Lung
43
Stomach Neoplasms
41
Pancreatic Neoplasms
41
Lymphoma
36
Uterine Cervical Neoplasms
35
Sarcoma, Synovial
35
Carcinoma, Renal Cell
35
Rhabdoid Tumor
34
Neurofibrosarcoma
34
Lung Neoplasms
34
Glioma
34
Lymphoma, Non-Hodgkin
33
Interventions
Standard of Care
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
STA 9090
1
SGN-LIV1A
1
Paclitaxel
1
MK 2206
1
Letrozole
1
Lasofoxifene
1
Irinotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Sarcoma
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT04055220
2026-02-17
REGOSTA
Centre Leon Berard
Phase NA
Recruiting
168 enrolled